智通财经7月9日电，市场监管总局、工业和信息化部印发《计量支撑产业新质生产力发展行动方案 （2025—2030年）》。其中提出，围绕宇航重大工程、商业航天、商用飞机、航空发动机、低空经济等 国家战略性新兴产业需求，开展航天器在轨运行、卫星遥感与通信、空间探测、商用飞机智能制造、低 空航空器等关键共性计量技术研究，研制空间用量子自然基准的原理样机并开展典型实验验证，解决空 间站长期在轨真空泄漏和材料放气率测量难题，攻克低空航空器智能感知、定位导航、能源动力等关键 参数测量校准技术，研究商用飞机、商业遥感与卫星互联网领域综合参数智能化检测和在线校准技术， 形成典型应用示范，带动航空航天技术协同创新。 两部门：开展航天器在轨运行、卫星遥感与通信、空间探测、商用飞机智能制造、低空航空器等关键共 性计量技术研究 ...

本报记者 吴奕萱 7月8日，宁波长鸿高分子科技股份有限公司（以下简称"长鸿高科"）发布公告称，公司正在筹划以发行 股份、可转换公司债券及支付现金的方式购买广西长科新材料有限公司（以下简称"广西长科"）100% 股权并同时募集配套资金。交易初步预计构成重大资产重组，不会导致公司实际控制人的变更，不构成 重组上市。长鸿高科股票自7月8日开市起停牌，预计停牌时间不超过10个交易日。 公开资料显示，广西长科是一家专注于特种合成树脂高分子材料研发、生产和销售的高新技术企业，产 品包括透明ABS（丙烯腈-丁二烯-苯乙烯共聚物）、高透明MS（甲基丙烯酸甲酯-苯乙烯共聚物）、高 腈AS（苯乙烯-丙烯腈共聚物）、高抗冲ABS/HIPS（聚苯乙烯）等特种树脂产品，公司还是国内少数 掌握透明ABS工业化量产本体法工艺的企业。 业内普遍认为，长鸿高科此次重组完成后，其行业竞争力将实现多维度跃升，这种变化主要体现在技 术、产品与产业链等方面。 中关村物联网产业联盟副秘书长袁帅在接受《证券日报》记者采访时表示："广西长科的透明ABS本体 法工艺不仅填补了长鸿高科在特种树脂高端制造领域的空白，其在特种树脂领域的技术积累还将与长鸿 高科形成 ...

Group 1 - The core point of the news is that Shaoyang Hydraulic plans to acquire 100% of Chongqing Xincheng Hangrui Technology Co., Ltd. through a combination of share issuance and cash payment, which is expected to constitute a major asset restructuring [2][10] - Shaoyang Hydraulic's stock has been suspended since June 23, and prior to the suspension, the stock price surged over 10% on June 20, indicating potential market interest in the upcoming acquisition [2][5] - The company reported an 11.93% increase in stock price over the 20 trading days leading up to the announcement, while the ChiNext Index and CITIC Machinery Index saw declines of 1.74% and 2.62%, respectively [5][6] Group 2 - The top ten shareholders of Shaoyang Hydraulic have seen significant changes, with several new individual investors appearing in the list, while notable foreign investment institutions like Morgan Stanley and UBS have reduced their holdings [4][7] - New shareholders Li Yuanfang and Cao Kangseng entered the top ten list, holding 724,200 shares and 537,750 shares, respectively, as of June 20 [9][10] - The financial performance of Xincheng Hangrui has been declining, with revenues of 353 million yuan and 347 million yuan in 2023 and 2024, respectively, and net profits of approximately 43.51 million yuan and 30.23 million yuan [10][11] Group 3 - The acquisition aims to seek new growth points for Shaoyang Hydraulic, leveraging Xincheng Hangrui's complete manufacturing process in forging and casting, which spans various industries including energy, aerospace, and military [10][14] - Post-acquisition, the two companies are expected to achieve process overlap and technical synergy, enhancing Shaoyang Hydraulic's flexible production capabilities and Xincheng Hangrui's ability to process various metal materials [14]

Core Viewpoint - The company, Maide Medical, is facing a significant decline in revenue and market challenges, particularly in its core safety infusion equipment segment, leading to concerns about its financial health and future prospects [2][3][4]. Revenue Performance - In 2024, Maide Medical's revenue plummeted by 42.77% year-on-year, totaling 275 million yuan, with core products experiencing substantial declines: safety infusion equipment revenue fell by 39.59%, and blood purification equipment revenue dropped to zero [2]. - The overall market for injection and puncture consumables in China shrank by 2.57% to 32 billion yuan, exacerbated by external pressures such as the FDA's safety reviews and tariffs on Chinese syringes [2]. Product Performance - The only bright spot was a 67.12% increase in revenue from blood purification connection machines, reaching 104 million yuan, although the average price halved from 20.78 million yuan to 8.01 million yuan [3]. - The shift towards lower-tier products in response to market demands raises concerns about the loss of technical premium and profitability [3]. Customer Concentration and Risks - The concentration of revenue among the top five customers increased, with the largest customer, Sanxin Medical, accounting for 32.65% of revenue (89.74 million yuan) and related transactions comprising 12.41% [3]. - The long repayment cycle of 1-3 years for major clients highlights potential liquidity risks for the company [3]. New Business Ventures - To counteract the decline in traditional business, Maide Medical is venturing into contact lens manufacturing through its subsidiary, Maide Shun, although this new business is currently in a cash-burning phase [4]. - Management expenses rose to 95 million yuan, and R&D expenses increased by 21.81% to 40 million yuan, with long-term loans of 30 million yuan fully invested in this new area [4]. Financial Health Indicators - Financial indicators are raising red flags, with inventory valued at 139 million yuan, constituting 22.99% of current assets, and a significant increase in contract liabilities by 78.59% to 98.84 million yuan [4]. - The company reported a goodwill impairment of 10.42 million yuan and a doubling of construction in progress to 50.01 million yuan, indicating potential asset bubble concerns [4].

证券研究报告 | 2025年07月02日 新和成（002001.SZ） 优于大市 技术与产业协同效应显著的综合性精细化工龙头 由校办工厂起家，新和成发展为全球化综合性精细化工龙头公司。1999 年新 和成由中学校办工厂新昌县合成化工厂发起设立，目前新和成已成长为维生 素、香精香料、蛋氨酸、高分子材料、原料药五大产业协同发展的全球化、 综合性精细化工龙头公司。 维生素与香精香料产业链相辅相成。新和成布局香精香料产业主要是基于产 业链协同发展思路，香精香料与维生素产业链存在多个共用中间体，技术协 同效应显著，香精香料业务是新和成维生素产业链的延伸与有机补充。例如， 芳樟醇既是香精香料板块的主要产品，又是 VE 生产的主要中间体；柠檬醛 也可作为香精香料的外销产品，又可用作自产 VA 的原材料。 蛋氨酸是承前启后的大单品，新和成已成为全球蛋氨酸行业龙头。承前：维 生素与蛋氨酸的下游客户群体高度重叠，两个产品具有较强的产业协同效 应，且蛋氨酸市场规模较大，技术门槛高，我国曾长期依赖进口，是此前亟 需国产化的营养品大单品。启后：蛋氨酸的关键技术是硫化和氰化工艺，新 和成将蛋氨酸领域积累的氰化技术有机迁移到新材料领域，尼 ...

证券代码：688053 证券简称：思科瑞 公告编号：2025-027 成都思科瑞微电子股份有限公司 关于和北京长鹰恒容电磁科技有限公司签署增资扩股意向 协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ??本次签订的意向协议系双方建立合作关系的初步意向，是各方进一步洽谈的 基础，本次增资的具体方案将由相关各方根据审计及评估结果进一步协商谈判，且正 式的协议签订尚需要履行必要的决策程序，故公司本次筹划的增资事项尚存在不确定 性。 ??成都思科瑞微电子股份有限公司（以下简称"公司""思科瑞"）拟向北京长 鹰恒容电磁科技有限公司（以下简称"长鹰恒容"）增资人民币5,210万元，增资完成 后，思科瑞持有长鹰恒容51.028%的股权。本次增资预计不构成《上市公司重大资产重 组管理办法》 规定的重大资产重组，也不构成关联交易。公司将根据交易事项后续进 展情况，按照《上海证券交易所科创板上市规则》、《公司章程》等相关规定，及时 履行相应的决策程序和信息披露义务。 ??目前本次增资事宜尚处于筹划阶段，在公司未完成 ...

如果您希望可以时常见面，欢迎标星收藏哦~ 来源：内容 编译自 semiengineering 。 随着人工智能 (AI) 工作负载日益庞大、复杂，用于处理所有数据的各种处理元件对功率的需求也 空前高涨。然而，高效可靠地提供这种功率，同时又不损害信号完整性或引入热瓶颈，却带来了半 导体历史上最严峻的设计和制造挑战。 与通用处理器不同，专为 AI 工作负载设计的芯片将密度推向极致。它们将更多晶体管封装到更小 的空间内，同时增加晶体管的总数（通常以芯片的形式）。其结果是更大、更密集的系统级封装， 其中电力传输不仅仅是一个电气问题，而是一个从单个芯片到服务器机架的封装、材料和系统集成 挑战。 由于内存和计算单元之间来回传输的数据量巨大，动态功耗占据主导地位。这些传输跨越庞大的内 存层级结构，使用各种高速互连。但移动所有这些数据是有代价的，这会产生层层叠加的设计约 束，从内存层级结构决策一直延伸到电源传输网络 (PDN)。 Imec研发副总裁Julien Ryckaert表示："随着我们转向背面和3D堆叠，热量变得更加局部化，也更 难消散。这种物理压缩加剧了电迁移和局部热点等挑战。" 为了使这些级别的电源传输易于处理， ...

证券代码：300522 证券简称：世名科技 苏州世名科技股份有限公司 投资者关系活动记录表 | 编号：2025-003 | | --- | | | 特定对象调研 ☐分析师会议 ☐媒体采访 ☐业绩说明会 | | --- | --- | | 投资者关系活动类别 | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | | 方正证券 林建东 天风证券 鲍荣富 | | | 东北证券 沈璐瑶 | | | 东财研究所 汪智谦 | | 参与单位名称及人员姓名 | 东方财富 庞月 | | | 东方财富 孟正超 | | | 华永信资本 朱大兵 | | | 灏盈投资 储达 | | 时间 | 2025年6月16日 15:00-17:00 | | 地点 | 公司行政楼十楼会议室 | | | 董事长、总裁：陆勇 | | | 董事、副总裁兼董事会秘书：吴鹏 | | 上市公司接待人员姓名 | 副总裁兼财务总监：苏卫岗 | | | 证券事务代表：吴远程 | | | 本次调研活动首先由公司董事、副总裁兼董事会秘书吴鹏先生对公 司发展历程、主营业务、主要产品等基本情况进行介绍，随后对投资 | ...

5月22日，内蒙古兴业银锡矿业股份有限公司（以下简称"兴业银锡"）召开业绩说明会。公司管理层就 核心业务增长逻辑、矿产储备、研发战略布局以及海外拓展规划等投资者关切的焦点问题展开深度解 读。 战略布局成效显著 依托于旗下优质在产矿山，兴业银锡实现了产量与效益双增长，战略布局成效显著。数据显示，2024 年，兴业银锡实现营业收入42.70亿元，同比增长15.23%；实现归属于上市公司股东的净利润15.30亿 元，同比增长57.82%。这一增长态势背后，是公司在核心业务板块多维度发力的结果。 例如，为了进一步加大对云南地区矿产资源的整合和开发，兴业银锡设立云南省麻栗坡锡贵金属矿业有 限公司，旨在依托云南丰富矿产资源优势，聚焦锡、铜等重点矿种，通过专业勘探团队与先进技术，推 进区域矿产资源高效整合与科学开发，为公司拓展西南市场、提升资源储备及产业竞争力奠定支点。 兴业银锡董事、副总裁兼董事会秘书孙凯对《证券日报》记者表示："2024年，公司设立了国际事业 部，专门负责推进海外业务。在资源选择上，公司以银、锡两大优势品种为核心，依托深厚技术储备与 市场需求潜力，同时布局铜、金资源，优化配置结构，推动资源开发多元协同发 ...

Core Viewpoint - After being acquired by Midea Group for four years, Wandong Medical has undergone a leadership change, with Hu Ziqiang resigning as chairman and being succeeded by Ma Chibing, both of whom are Midea Group executives [2][3]. Group 1: Leadership Changes - Hu Ziqiang has resigned from his positions at Wandong Medical due to personal reasons, effective immediately, and will no longer hold any roles within the company [2]. - Ma Chibing, who has over 20 years of experience at Midea Group, has been appointed as the new chairman of Wandong Medical [2][3]. - Hu Ziqiang previously served as Midea Group's Vice President and CTO, while Ma Chibing has held various leadership roles within Midea, including overseeing the cleaning appliance division [3]. Group 2: Financial Performance - In 2024, Wandong Medical reported a revenue of 1.524 billion yuan, marking a 23.26% year-on-year increase, the largest revenue growth in the past decade [6]. - Despite the revenue growth, the company's net profit attributable to shareholders decreased by 16.54% to 157 million yuan in 2024, following a trend of declining net profits over the past three years [6]. - The company has experienced a decline in gross profit margin each year, with costs increasing significantly, particularly in the context of a shift towards higher-end products [6][7]. Group 3: Market Strategy - Wandong Medical is focusing on expanding into the mid-to-high-end market, with a strategic plan to strengthen its domestic foundation while also targeting international markets [6]. - The company has established a "5+1" regional layout for overseas markets, achieving a revenue of 233 million yuan from international sales, which represents a 68.36% increase year-on-year [7]. - However, the costs associated with this international expansion have risen sharply, with a 108.38% increase in corresponding costs, leading to a decrease in gross margin [7].